New combo offers hope for Hard-to-Treat GI cancers
NCT ID NCT05205330
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or stop them from growing. About 107 participants will receive the treatment, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, 56126, Italy
-
Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.